Qing Dao Shi

This research investigates how weight loss through a diet management mobile app and an intelligent weight scale affects cardiovascular health in obese patients with heart failure. The study focuses on patients with heart failure with reduced ejection fraction and aims to see if these tools can reduce death rates, hospital stays related to heart failure, and improve frailty and quality of life. The trial addresses a gap where current heart failure guidelines recognize obesity as a risk but lack effective interventions for this group. Participants are randomly assigned to one of two groups: one group uses a fully functional diet management app and intelligent weight scale designed to support weight loss in obese heart failure patients, while the other group uses limited-function versions of the app and scale as a comparison. Both groups use the app at every meal and the scale daily for 12 months. The trial is a multicenter, single-blind randomized controlled study. During the study, participants will visit the clinic after 12 months for checkups. Researchers will collect data on a composite cardiovascular outcome, including all-cause mortality and hospitalizations related to heart failure, tracked over one year. Adherence to app and scale use is monitored through the mobile application. The study measures the impact on heart failure frailty, quality of life, and overall cardiovascular outcomes over the trial period.

Researchers are conducting a multicenter, prospective, observational real-world study across 200 hospitals in China to examine treatment patterns for chronic hepatitis B (CHB). The study aims to compare patient outcomes under various therapies to provide evidence-based data that can help optimize CHB treatment and follow-up, with the ultimate goal of advancing a functional cure for chronic hepatitis B. The focus includes monitoring the incidence of hepatocellular carcinoma (HCC) associated with hepatitis B. Participants receive treatments including entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF), or Peginterferon α-2b injection. The study follows both patients currently on these therapies and those initiating or re-initiating Peginterferon α-2b therapy. These treatments are assessed in routine clinical practice settings without intervention from the study team. Throughout the study, patients are monitored from week 4 up to week 240 for the development of HBsAg-associated hepatocellular carcinoma (HCC) and overall HCC incidence. Researchers collect data on treatment effectiveness and safety as part of the observational follow-up. Participants provide informed consent and are observed under real-world conditions to evaluate long-term outcomes and risks associated with chronic hepatitis B and its treatments.